Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 12 years, it is emailed daily to more than 10,000 pharma industry professionals throughout Australia and NZ.

For just $429.95 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Special Report
PBAC March outcomes in full
In a meeting that saw 22 major medicines submissions, positive and negative results were equally mixed with nine of each plus two deferrals and two no results because of a lack of data from the TGA.
Pipeline Monitor
FDA shoots down Olumiant
The FDA has surprised by rejecting Lilly and Incyte's oral rheumatoid arthritis drug Olumiant, diverging from the EU's approval of the drug in February.
Approvals Action
Keytruda wins another indication
The TGA has revealed the granting of a new indication to MSD's blockbuster cancer drug Keytruda and CSL's new product Afstyla has been approved for treating haemophilia A.